Ferinject® (ferric carboxymaltose) is an intravenous (i.v.) iron indicated for the treatment of iron deficiency and iron deficiency anaemia, where oral iron is ineffective or cannot be used or when there is a clinical need to deliver iron rapidly.

Among others, iron deficiency and iron deficiency anaemia are especially common in patients who suffer from chronic kidney disease (CKD), heart failure and inflammatory bowel disease. It is also a condition affecting patients in preoperative and perioperative situations, as well as premenopausal women, including women affected by heavy menstrual bleeding and in peri-partum.

In the U.S., Ferinject® is commercialised under the brand name Injectafer®. Ferinject® has received market approval in 82 countries.

How does Ferinject® work?

The active ingredient of Ferinject®, ferric carboxymaltose, is composed of a poly-nuclear iron core stabilised by a carboxymaltose shell that ensures an effective iron utilisation. When injected, this complex releases the iron, which will be either stored or exported in the blood plasma for transportation and utilisation where it is needed.